Topical PDT utilizing ALA 20%-EDTA 2%-DMSO 2% as the photosensitizer and VersaLight as the light source is a noninvasive, nearly painless treatment with excellent therapeutic and cosmetic results. Our data show the efficiency of this therapy for patients with certain subtypes of BCC, SCC, and Bowen's disease.

Cryotherapy with an integrated sensor for temperature control is an effective, safe, and precise treatment, allowing for a 100% short-term cure rate of AKs.

The purpose of this study was to measure the changes in Intra-Abdominal Pressure (IAP) during abdominoplasty and the relevance of these changes to the immediate postoperative recovery period. Eighteen patients (17 females and one male) who underwent abdominoplasty for aesthetic reasons participated in the study. The data collected included measurements of height, weight, and measurements of the intra-urinary bladder pressure prior to surgery, immediately post operative, and 18-24 hours postoperative. Changes in tidal volume and ventilation pressures were also measured prior to surgery and immediately postoperative. The weight of the excised tissue ranged between 1150 g-6500 g with an average of 2700 g. Three patients had significant diasthesis recti repair during surgery. In these patients the measured intra-vesicular pressure was above 24 cm of H(2)O by the end of the operation and above 20 cm of H(2)O the day following surgery. Two out of the three patients were treated with anticoagulants and the symptoms subsided within a week. The third patient recovered spontaneously by the third day. In conclusion, patients with an intra-urinary bladder pressure above 20 cm of H(2)O following abdominoplasty were felt to be at significant risk for development of respiratory distress in the immediate postoperative period.

The therapeutic response induced by perilesional PEG-IL-2 injections was found to be an encouraging, safe, and well-tolerated treatment of BCC. Further studies including a larger patient population and long-term follow-up are necessary in order to substantiate these findings.

Seventy‐one patients (52 patients with psoriasis capitis and 19 with scalp seborrheic dermatitis) enrolled in this open‐label study. All had stable disease for at least 6 months. Patients who were allergic to imidazoles, were pregnant or breastfeeding, or were aged less than 18 years were excluded. Only psoriatic patients with scalp involvement alone or whose body surface area involvement was less than 25% were included. All patients reported incomplete response to previous topical therapies (used alone or in combination: corticosteroids, salicylic acid, tar, anthralin, and ketoconazole shampoo) and had a washout period of at least 1 month. The patients applied 40% urea plus 1% bifonazole in an ointment base nightly. They were instructed to apply a fixed amount (1 cm in length = 0.32 g) of ointment for each 10 cm 2of involved area. Each morning, 1% bifonazole shampoo was applied for 5 min and rinsed with water; 10–20 min later, one drop of 1% bifonazole solution per 10 cm 2area was applied to the scalp. This treatment regimen was repeated daily for 7 days. If clearance was not achieved in the first week, the regimen was continued for one more week. After this initial treatment (for 7 or 14 days), maintenance therapy with once‐weekly application of the regimen was continued for up to 3 months. In addition, during this follow‐up period, the scalp was washed in 2‐day intervals with the shampoo alone, which was left on for 5 min and then washed off. On each visit (weeks 0, 1, 2 and 12), the scalp was evaluated for redness, scaling, and pruritus and each parameter was scored as absent (0), mild 1, moderate 2, or severe 3. On each visit, the scalp's condition was scored as follows: worsening (− 1), no improvement (0), mild (0–25%) improvement 1, moderate (25–50%) improvement 2, marked (50–75%) improvement 3, and (> 75%) cleared 4.